The price of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares last traded on Wall Street rose 14.41% to $9.53.
RXRX stock price is now 46.90% away from the 50-day moving average and 21.34% away from the 200-day moving average. The market capitalization of the company currently stands at $2.06B.
With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX).
In other news, Secora Michael, Chief Financial Officer sold 25,000 shares of the company’s stock on Dec 13. The stock was sold for $189,770 at an average price of $7.59. Upon completion of the transaction, the Chief Financial Officer now directly owns 956,014 shares in the company, valued at $9.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 12, Chief Financial Officer Secora Michael sold 25,000 shares of the business’s stock. A total of $184,868 was realized by selling the stock at an average price of $7.39. This leaves the insider owning 943,514 shares of the company worth $8.99 million. Insiders disposed of 1,847,937 shares of company stock worth roughly $17.61 million over the past 1 year. A total of 30.30% of the company’s stock is owned by insiders.
During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.54 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 4.28, and a quick ratio of 4.28. The fifty day moving average price for RXRX is $6.49 and a two-hundred day moving average price translates $7.85 for the stock.
The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.43, missing analysts’ expectations of -$0.38 by -0.05. This compares to -$0.35 EPS in the same period last year. The net profit margin was -617.74% and return on equity was -70.84% for RXRX. The company reported revenue of $10.53 million for the quarter, compared to $13.16 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -19.96 percent. For the current quarter, analysts expect RXRX to generate $20.53M in revenue.
